CLAIMS

- 1. A host cell containing a recombinant expression vector, said vector encoding a protein comprising at least a portion of a *Clostridium botulinum* toxin, said toxin selected from the group consisting of type B toxin and type E toxin.
- 5 2. The host cell of Claim 1, wherein and said host cell is capable of expressing said protein at a level greater than or equal to 5% of the total cellular protein.

10

- 3. The host cell of Claim 1, wherein and said host cell is capable of expressing said protein as a soluble protein at a level greater than or equal to 0.25% of the total soluble cellular protein.
- 4. The host cell of Claim 1, wherein said host cell is an Escherichia coli cell.
 - 5. The host cell of Claim 1, wherein said host cell is an insect cell.
 - 6. The host cell of Claim 1, wherein said host cell is a yeast cell.
- 7. A host cell containing a recombinant expression vector, said vector encoding a fusion protein comprising a non-toxin protein sequence and at least a portion of a *Clostridium botulinum* toxin, said toxin selected from the group consisting of type B toxin and type E toxin.
- 8. The host cell of Claim 7, wherein said portion of said toxin comprises the receptor binding domain.

- 9. The host cell of Claim 7, wherein said non-toxin protein sequence comprises a poly-histidine tract.
- 10. A vaccine comprising a fusion protein, said fusion protein comprising a non-toxin protein sequence and at least a portion of a *Clostridium botulinum* toxin, said toxin selected from the group consisting of type B toxin and type E toxin.
- 11. The vaccine of Claim 10 further comprising a fusion protein comprising a non-toxin protein sequence and at least a portion of *Clostridium botulinum* type A toxin.
- 12. The vaccine of Claim 10, wherein said portion of said Clostridium botulinum toxin comprises the receptor binding domain.
 - 13. The vaccine of Claim 10 wherein said non-toxin protein sequence comprises a poly-histidine tract.
 - 14. The vaccine of Claim 10, wherein said vaccine is substantially endotoxin-free.
- 15. A method of generating antibody directed against a Clostridium botulinum toxin comprising:
 - a) providing in any order:
 - i) an antigen comprising a fusion protein comprising a non-toxin protein sequence and at least a portion of a *Clostridium botulinum* toxin, said toxin selected from the group consisting of type B toxin and type E toxin, and

5

10

- ii) a host; and
- b) immunizing said host with said antigen so as to generate an antibody.
- The method of Claim 15, wherein said antigen further comprises a
 fusion protein comprising a non-toxin protein sequence and at least a portion of
 Clostridium botulinum type A toxin.
 - 17. The method of Claim 15, wherein said portion of said *Clostridium* botulinum toxin comprises the receptor binding domain.
- 18. The method of Claim 15 wherein said non-toxin protein sequence comprises a poly-histidine tract.
 - 19. The method of Claim 15 wherein said host is a mammal.
 - 20. The method of Claim 19 wherein said mammal is a human.
 - 21. The method of Claim 15 further comprising step c) collecting said antibodies from said host.
- 15 22. The method of Claim 21 further comprising step d) purifying said antibodies.
 - 23. The antibody raised according to the method of Claim 15.
 - 24. The antibody raised according to the method of Claim 16.